vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $273.0M, roughly 1.5× Forestar Group Inc.). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 5.6%, a 54.8% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 9.0%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $-157.1M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs -9.6%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...

BCRX vs FOR — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.5× larger
BCRX
$406.6M
$273.0M
FOR
Growing faster (revenue YoY)
BCRX
BCRX
+200.1% gap
BCRX
209.1%
9.0%
FOR
Higher net margin
BCRX
BCRX
54.8% more per $
BCRX
60.5%
5.6%
FOR
More free cash flow
BCRX
BCRX
$448.3M more FCF
BCRX
$291.2M
$-157.1M
FOR
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
-9.6%
FOR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
FOR
FOR
Revenue
$406.6M
$273.0M
Net Profit
$245.8M
$15.4M
Gross Margin
97.7%
20.1%
Operating Margin
64.0%
7.6%
Net Margin
60.5%
5.6%
Revenue YoY
209.1%
9.0%
Net Profit YoY
1017.5%
-6.7%
EPS (diluted)
$1.13
$0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
FOR
FOR
Q4 25
$406.6M
$273.0M
Q3 25
$159.4M
$670.5M
Q2 25
$163.4M
$390.5M
Q1 25
$145.5M
$351.0M
Q4 24
$131.5M
$250.4M
Q3 24
$117.1M
$551.3M
Q2 24
$109.3M
$318.4M
Q1 24
$92.8M
$333.8M
Net Profit
BCRX
BCRX
FOR
FOR
Q4 25
$245.8M
$15.4M
Q3 25
$12.9M
$86.9M
Q2 25
$5.1M
$32.9M
Q1 25
$32.0K
$31.6M
Q4 24
$-26.8M
$16.5M
Q3 24
$-14.0M
$81.5M
Q2 24
$-12.7M
$38.7M
Q1 24
$-35.4M
$45.0M
Gross Margin
BCRX
BCRX
FOR
FOR
Q4 25
97.7%
20.1%
Q3 25
98.6%
22.3%
Q2 25
98.3%
20.4%
Q1 25
96.9%
22.6%
Q4 24
95.4%
22.0%
Q3 24
97.3%
23.9%
Q2 24
98.4%
22.5%
Q1 24
98.6%
24.9%
Operating Margin
BCRX
BCRX
FOR
FOR
Q4 25
64.0%
7.6%
Q3 25
18.6%
16.9%
Q2 25
18.2%
11.2%
Q1 25
14.6%
11.6%
Q4 24
-3.4%
8.7%
Q3 24
6.6%
19.7%
Q2 24
8.0%
16.2%
Q1 24
-15.6%
17.6%
Net Margin
BCRX
BCRX
FOR
FOR
Q4 25
60.5%
5.6%
Q3 25
8.1%
13.0%
Q2 25
3.1%
8.4%
Q1 25
0.0%
9.0%
Q4 24
-20.4%
6.6%
Q3 24
-12.0%
14.8%
Q2 24
-11.6%
12.2%
Q1 24
-38.1%
13.5%
EPS (diluted)
BCRX
BCRX
FOR
FOR
Q4 25
$1.13
$0.30
Q3 25
$0.06
$1.70
Q2 25
$0.02
$0.65
Q1 25
$0.00
$0.62
Q4 24
$-0.13
$0.32
Q3 24
$-0.07
$1.59
Q2 24
$-0.06
$0.76
Q1 24
$-0.17
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
FOR
FOR
Cash + ST InvestmentsLiquidity on hand
$274.7M
$211.7M
Total DebtLower is stronger
$793.2M
Stockholders' EquityBook value
$-119.2M
$1.8B
Total Assets
$514.2M
$3.2B
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
FOR
FOR
Q4 25
$274.7M
$211.7M
Q3 25
$212.9M
$379.2M
Q2 25
$260.0M
$189.2M
Q1 25
$295.1M
$174.3M
Q4 24
$320.9M
$132.0M
Q3 24
$96.8M
$481.2M
Q2 24
$78.4M
$359.2M
Q1 24
$84.3M
$416.2M
Total Debt
BCRX
BCRX
FOR
FOR
Q4 25
$793.2M
Q3 25
$802.7M
Q2 25
$872.8M
Q1 25
$872.5M
Q4 24
$806.8M
Q3 24
$706.4M
Q2 24
$706.1M
Q1 24
$705.7M
Stockholders' Equity
BCRX
BCRX
FOR
FOR
Q4 25
$-119.2M
$1.8B
Q3 25
$-387.9M
$1.8B
Q2 25
$-421.6M
$1.7B
Q1 25
$-451.9M
$1.6B
Q4 24
$-475.9M
$1.6B
Q3 24
$-468.6M
$1.6B
Q2 24
$-475.6M
$1.5B
Q1 24
$-476.2M
$1.5B
Total Assets
BCRX
BCRX
FOR
FOR
Q4 25
$514.2M
$3.2B
Q3 25
$446.4M
$3.1B
Q2 25
$457.2M
$3.1B
Q1 25
$480.0M
$3.0B
Q4 24
$490.4M
$3.0B
Q3 24
$491.3M
$2.8B
Q2 24
$472.4M
$2.7B
Q1 24
$467.9M
$2.6B
Debt / Equity
BCRX
BCRX
FOR
FOR
Q4 25
0.44×
Q3 25
0.45×
Q2 25
0.52×
Q1 25
0.53×
Q4 24
0.50×
Q3 24
0.44×
Q2 24
0.47×
Q1 24
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
FOR
FOR
Operating Cash FlowLast quarter
$292.0M
$-157.0M
Free Cash FlowOCF − Capex
$291.2M
$-157.1M
FCF MarginFCF / Revenue
71.6%
-57.5%
Capex IntensityCapex / Revenue
0.2%
0.0%
Cash ConversionOCF / Net Profit
1.19×
-10.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M
$93.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
FOR
FOR
Q4 25
$292.0M
$-157.0M
Q3 25
$41.6M
$256.3M
Q2 25
$41.3M
$15.8M
Q1 25
$-27.5M
$-19.8M
Q4 24
$-5.2M
$-450.0M
Q3 24
$8.2M
$119.2M
Q2 24
$-1.4M
$-61.7M
Q1 24
$-53.7M
$-59.2M
Free Cash Flow
BCRX
BCRX
FOR
FOR
Q4 25
$291.2M
$-157.1M
Q3 25
$40.3M
$255.6M
Q2 25
$41.1M
$15.0M
Q1 25
$-27.7M
$-20.5M
Q4 24
$-5.9M
Q3 24
$8.2M
$118.4M
Q2 24
$-1.5M
$-62.3M
Q1 24
$-53.9M
$-59.8M
FCF Margin
BCRX
BCRX
FOR
FOR
Q4 25
71.6%
-57.5%
Q3 25
25.3%
38.1%
Q2 25
25.2%
3.8%
Q1 25
-19.0%
-5.8%
Q4 24
-4.5%
Q3 24
7.0%
21.5%
Q2 24
-1.4%
-19.6%
Q1 24
-58.1%
-17.9%
Capex Intensity
BCRX
BCRX
FOR
FOR
Q4 25
0.2%
0.0%
Q3 25
0.8%
0.1%
Q2 25
0.1%
0.2%
Q1 25
0.1%
0.2%
Q4 24
0.5%
0.0%
Q3 24
0.1%
0.1%
Q2 24
0.1%
0.2%
Q1 24
0.3%
0.2%
Cash Conversion
BCRX
BCRX
FOR
FOR
Q4 25
1.19×
-10.19×
Q3 25
3.23×
2.95×
Q2 25
8.12×
0.48×
Q1 25
-859.91×
-0.63×
Q4 24
-27.27×
Q3 24
1.46×
Q2 24
-1.59×
Q1 24
-1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

Segment breakdown not available.

FOR
FOR

D.R.Horton Inc.$183.8M67%
Other$89.2M33%

Related Comparisons